A stem cell transplant effectively reduced the abnormal immune response that drives multiple sclerosis (MS) progression by altering a specific group of immune cells called myeloid cells, a mouse study showed. Treatment with a compound that suppressed a receptor called CSF1R improved the transplantation efficiency of myeloid cells…

A new imaging technique was able to detect inflammation in a mouse model of multiple sclerosis (MS) before disease symptoms appeared, and to monitor the animals’ responses to treatment, a study reports. “With this new non-invasive imaging approach, we can detect toxic inflammation that could help us better understand…

Attaching a kind of molecule backpack to myeloid cells — a type of immune cells involved in the inflammatory attack that drives multiple sclerosis (MS) — may help to halt inflammation and damage in the brain in MS by modulating immune cell activity, a study…

Unusual growth in an immune cell class called myeloid cells is evident in the bone marrow of people with multiple sclerosis (MS), and these cells likely contribute to the inflammation that drives the disease, according to a new study. Experiments in mice suggest that myelin-reactive T-cells can migrate to the bone…

A medication currently approved to treat certain kinds of cancer, called topotecan, could be repurposed for treating neuroinflammatory conditions such as multiple sclerosis (MS) because it reduces the inflammatory activity of immune cells called microglia. That’s according to the study, “Myeloid cell-specific topoisomerase 1 inhibition using DNA origami…

An increased production of CD25 – an immune receptor that regulates T-cell proliferation and activation – is the most noticeable blood cell immune alteration in people with multiple sclerosis (MS) compared with their unaffected identical twins, a study discovered. The increased CD25 levels, which correlated with disease severity, were…

A class of immune cells called myeloid cells that express the inflammatory protein SIGLEC1 may be able to distinguish between active and chronic multiple sclerosis (MS) brain lesions, a study found. The study, “SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood…

Previously unknown immune cell subtypes are present in the inflamed brain of mice models of multiple sclerosis (MS), a new study reports. According to the researchers, these subsets of myeloid cells (cells derived from hematopoietic stem cells in the bone marrow) can offer a strong basis for therapeutic targets in neuroinflammatory and…

Innate Immunotherapeutics, Ltd., announced that it has completed patient enrollment in its ongoing Phase 2B, placebo-controlled clinical trial assessing the efficacy and safety of the drug MIS416 as a once-weekly treatment for secondary progressive multiple sclerosis (SPMS). MIS416 is a biologically derived immune modulator that targets myeloid cells, a subset of innate immune cells that can…

In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated the impact of fingolimod (Gilenya, Novartis), an approved drug for multiple sclerosis (MS), on the reactivity of myeloid cells, a key group that comprises several immune cells that…